Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. (2020)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-020-18636-w
PubMed Identifier: 32973176
Publication URI: http://europepmc.org/abstract/MED/32973176
Type: Journal Article/Review
Volume: 11
Parent Publication: Nature communications
Issue: 1
ISSN: 2041-1723